Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKesson
McKinsey
Colorcon
Express Scripts

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Patent: 10,259,859

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,259,859
Title:Constructs having a SIRP-.alpha. domain or variant thereof
Abstract: The present disclosure features signal-regulatory protein .alpha. (SIRP-.alpha.) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-.alpha. constructs include a high affinity SIRP-.alpha. D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-.alpha.. The SIRP-.alpha. polypeptides or constructs include a SIRP-.alpha. D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein .alpha. (SIRP-.alpha.) D1 variant and (ii) an antibody.
Inventor(s): Pons; Jaume (San Carlos, CA), Deming; Laura (Palo Alto, CA), Goodman; Corey (Marshall, CA), Sim; Bang Janet (Brisbane, CA), Kauder; Steven Elliot (San Mateo, CA), Wan; Hong (Foster City, CA), Kuo; Tracy Chia-Chien (San Mateo, CA)
Assignee: ALX ONCOLOGY INC. (Burlingame, CA)
Application Number:15/230,186
Patent Claims:see list of patent claims

Details for Patent 10,259,859

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2035-08-07
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Free Forever Trial 2035-08-07
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Free Forever Trial 2035-08-07
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2004-02-12 ⤷  Free Forever Trial 2035-08-07
Eli Lilly And Company ERBITUX cetuximab Injection 125084 2007-03-28 ⤷  Free Forever Trial 2035-08-07
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Free Forever Trial 2035-08-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Boehringer Ingelheim
McKesson
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.